Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 184-189

  Fennell, Dean A ^a   Parmar, Amit ^a   Shamash, Jonathan ^a   Evans, Marie T ^a   Sheaff, Michael T ^a   Sylvester, Richard ^a   Dhaliwal, Kevin ^a   Gower, Nicole ^a   Steele, Jeremy ^a   Rudd, Robin ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IRINOTECAN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MITOMYCIN; PLATINUM COMPLEX; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; EUROPE; FEMALE; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; PLEURA TUMOR; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL RATE; THEORETICAL MODEL; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; CLINICAL TRIALS, PHASE II; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MESOTHELIOMA; MIDDLE AGED; MITOMYCIN; MODELS, THEORETICAL; ORGANOPLATINUM COMPOUNDS; PLEURAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINBLASTINE;

EID: 16644377286     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.050     Document Type: Article

References (19)

1. Peto J, Decarli A, La Vecchia C, et al: The European mesothelioma epidemic. Br J Cancer 79:666-672, 1999
2. Alberts AS, Falkson G, Goedhals L, et al: Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 6:527-535, 1988
3. Fennell DA, Rudd RM: Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: Opportunities for effective drug development. Lancet Oncol 5:354-362, 2004
4. Antman K, Shemin R, Ryan L, et al: Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 6:147-153, 1988
5. Chailleux E, Dabouis G, Pioche D, et al: Prognostic factors in diffuse malignant pleural mesothelioma: A study of 167 patients. Chest 93:159-162, 1988
6. Ruffie P, Feld R, Minkin S, et al: Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol 7:1157-1168, 1989
7. Boutin C, Rey F, Gouvernet J, et al: Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 72:394-404, 1993
8. Fusco V, Ardizzoni A, Merlo F, et al: Malignant pleural mesothelioma: Multivariate analysis of prognostic factors on 113 patients. Anticancer Res 13:683-689, 1993
9. Herndon JE, Green MR, Chahinian AP, et al: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113:723-731, 1998
10. Edwards JG, Abrams KR, Leverment JN, et al: Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax 55:731-735, 2000
11. Ceresoli GL, Locati LD, Ferreri AJ, et al: Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 34:279-287, 2001
12. Metintas M, Metintas S, Ucgun I, et al: Prognostic factors in diffuse malignant pleural mesothelioma: Effects of pretreatment clinical and laboratory characteristics. Respir Med 95:829-835, 2001
13. Steele JP: Prognostic factors in mesothelioma. Semin Oncol 29:36-40, 2002
14. Curran D, Sahmoud T, Therasse P, et al: Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16:145-152, 1998
15. Steele JP, Shamash J, Evans MT, et al: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912-3917, 2000
16. Fennell D, Steele J, Shamash J, et al: Second line therapy of malignant pleural mesothelioma with irinotecan, cisplatin, and mitomycin C (IPM): A phase II study. Lung Cancer 41:5221, 2003 (suppl 2, abstr P-518)
17. Fennell D, Steele J, Shamash J, et al: A phase Il study of irinotecan, cisplatin, and mitomycin C (IPM) in malignant pleural mesothelioma. Lung Cancer 41:5221, 2003 (suppl 2, abstr P-517)
18. Muers MF, Rudd RM, O'Brien ME, et al: BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 59:144-148, 2004
19. Middleton GW, Smith IE, O'Brien ME, et al: Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9:269-273, 1998